Karl Landsteiner Private University of Health Sciences   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Krems Austria (2013)

Organization Overview

First Clinical Trial
2014
NCT02178449
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Karl Landsteiner University of Health Sciences | Karl Landsteiner University of Health Sciences, University Hospital of St. Poelten, St. Poelten, Austria | Landesklinikum Sankt Polten

Active Ingredients

Drugs in Phase 4 Trials (2)

ropivacaine (naropin) (1 trial)

urea (1 trial)

Drugs in Phase 2 Trials (1)

methoxsalen (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Mycoses (Phase 2)

Mycosis Fungoides (Phase 2)

Sezary Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3